Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
INeo-Vac-P01 by Hangzhou Neoantigen Therapeutics for Esophageal Cancer: Likelihood of Approval
INeo-Vac-P01 is under clinical development by Hangzhou Neoantigen Therapeutics and currently in Phase I for Esophageal Cancer. According to GlobalData,...
Data Insights
INeo-Vac-P01 by Hangzhou Neoantigen Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval
INeo-Vac-P01 is under clinical development by Hangzhou Neoantigen Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...